{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:16:37Z","timestamp":1792451797978,"version":"4.5.0"},"reference-count":65,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/08\/60"],"award-info":[{"award-number":["14\/08\/60"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Transurethral resection of bladder tumour has been the mainstay of bladder cancer staging for &gt;\u00a060 years. Staging inaccuracies are commonplace, leading to delayed treatment of muscle-invasive bladder cancer. Multiparametric magnetic resonance imaging offers rapid, accurate and non-invasive staging of muscle-invasive bladder cancer, potentially reducing delays to radical treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title>\n<jats:p>To assess the feasibility and efficacy of the introducing multiparametric magnetic resonance imaging ahead of transurethral resection of bladder tumour in the staging of suspected muscle-invasive bladder cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Design<\/jats:title>\n<jats:p>Open-label, multistage randomised controlled study in three parts: feasibility, intermediate and final clinical stages. The COVID pandemic prevented completion of the final stage.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Setting<\/jats:title>\n<jats:p>Fifteen UK hospitals.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Participants<\/jats:title>\n<jats:p>Newly diagnosed bladder cancer patients of age\u00a0\u2265\u00a018 years.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Interventions<\/jats:title>\n<jats:p>Participants were randomised to Pathway 1 or 2 following visual assessment of the suspicion of non-muscle-invasive bladder cancer or muscle-invasive bladder cancer at the time of outpatient cystoscopy, based upon a 5-point Likert scale: Likert 1\u20132 tumours considered probable non-muscle-invasive bladder cancer; Likert 3\u20135 possible muscle-invasive bladder cancer. In Pathway 1, all participants underwent transurethral resection of bladder tumour. In Pathway 2, probable non-muscle-invasive bladder cancer participants underwent transurethral resection of bladder tumour, and possible muscle-invasive bladder cancer participants underwent initial multiparametric magnetic resonance imaging. Subsequent therapy was determined by the treating team and could include transurethral resection of bladder tumour.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-7\"><jats:title>Main outcome measures<\/jats:title>\n<jats:p>Feasibility stage: proportion with possible muscle-invasive bladder cancer randomised to Pathway 2 which correctly followed the protocol.<\/jats:p>\n<jats:p>Intermediate stage: time to correct treatment for muscle-invasive bladder cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-8\"><jats:title>Results<\/jats:title>\n<jats:p>Between 31 May 2018 and 31 December 2021, of 638 patients approached, 143 participants were randomised; 52.1% were deemed as possible muscle-invasive bladder cancer and 47.9% probable non-muscle-invasive bladder cancer. Feasibility stage: 36\/39 [92% (95% confidence interval 79 to 98%)] muscle-invasive bladder cancer participants followed the correct treatment by pathway. Intermediate stage: median time to correct treatment was 98 (95% confidence interval 72 to 125) days for Pathway 1 versus 53 (95% confidence interval 20 to 89) days for Pathway 2 [hazard ratio 2.9 (95% confidence interval 1.0 to 8.1)], <jats:italic>p<\/jats:italic> = 0.040. Median time to correct treatment for all participants was 37 days for Pathway 1 and 25 days for Pathway 2 [hazard ratio 1.4 (95% confidence interval 0.9 to 2.0)].<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-9\"><jats:title>Limitations<\/jats:title>\n<jats:p>For participants who underwent chemotherapy, radiotherapy or palliation for multiparametric magnetic resonance imaging-diagnosed stage T2 or higher disease, it was impossible to conclusively know whether these were correct treatments due to the absence of histopathologically confirmed muscle invasion, this being confirmed radiologically in these cases. All patients had histological confirmation of their cancers.<\/jats:p>\n<jats:p>Due to the COVID-19 pandemic, we were unable to realise the final stage.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-10\"><jats:title>Conclusion<\/jats:title>\n<jats:p>The multiparametric magnetic resonance imaging-directed pathway led to a substantial 45-day reduction in time to correct treatment for muscle-invasive bladder cancer, without detriment to non-muscle-invasive bladder cancer participants. Consideration should be given to the incorporation of multiparametric magnetic resonance imaging ahead of transurethral resection of bladder tumour into the standard pathway for all patients with suspected muscle-invasive bladder cancer. The improved decision-making accelerated time to treatment, even though many patients subsequently needed transurethral resection of bladder tumour. A proportion of patients can avoid transurethral resection of bladder tumour completely, reducing costs and morbidity, given the much lower cost of magnetic resonance imaging and biopsy compared to transurethral resection of bladder tumour.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-11\"><jats:title>Future work<\/jats:title>\n<jats:p>Further work to cross-correlate with the recently developed Vesical Imaging-Reporting and Data System will improve accuracy and aid dissemination. Longer follow-up to examine the effect of the pathway on outcomes is also required. Incorporation of liquid deoxyribonucleic acid-based biomarkers may further improve the quality of decision-making and should also be investigated further.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-12\"><jats:title>Study registration<\/jats:title>\n<jats:p>This study is registered as ISRCTN 35296862.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-13\"><jats:title>Funding<\/jats:title>\n<jats:p>This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 14\/08\/60) and is published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 28, No. 42. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/deht5407","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T08:38:40Z","timestamp":1725871120000},"page":"1-65","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-8204","authenticated-orcid":true,"given":"Nicholas","family":"James","sequence":"first","affiliation":[{"name":"Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-2230","authenticated-orcid":true,"given":"Sarah","family":"Pirrie","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-2053","authenticated-orcid":true,"given":"Wenyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-8828","authenticated-orcid":true,"given":"James","family":"Catto","sequence":"additional","affiliation":[{"name":"Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0029-8359","authenticated-orcid":true,"given":"Kieran","family":"Jefferson","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2882-5990","authenticated-orcid":true,"given":"Prashant","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-9422","authenticated-orcid":true,"given":"Ana","family":"Hughes","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-3294","authenticated-orcid":true,"given":"Ann","family":"Pope","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-822X","authenticated-orcid":true,"given":"Veronica","family":"Nanton","sequence":"additional","affiliation":[{"name":"Medical School, University of Warwick, Warwick, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1583-6268","authenticated-orcid":true,"given":"Harriet P","family":"Mintz","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-9547","authenticated-orcid":true,"given":"Allen","family":"Knight","sequence":"additional","affiliation":[{"name":"Patient and Public Involvement Representatives, Gallagher, Bradford Knight, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6308-2292","authenticated-orcid":true,"given":"Jean","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Patient and Public Involvement Representatives, Gallagher, Bradford Knight, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-4293","authenticated-orcid":true,"given":"Richard T","family":"Bryan","sequence":"additional","affiliation":[{"name":"Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2024,8]]},"reference":[{"key":"key2024091819533000_ref1-bib1","volume-title":"CRUK Cancerstats: Bladder Cancer","year":"2014"},{"key":"key2024091819533000_ref2-bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2019.01.031","article-title":"Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method","volume":"76","author":"Bessa","year":"2019","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref3-bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2014.02.031","article-title":"So much cost, such little progress","volume":"66","author":"Bryan","year":"2014","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref4-bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrurol.2013.180","article-title":"The future of bladder cancer care in the USA","volume":"11","author":"Kaplan","year":"2014","journal-title":"Nat Rev Urol"},{"key":"key2024091819533000_ref5-bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref6-bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"EAU guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref7-bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"key2024091819533000_ref8-bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref9-bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2014.06.083","article-title":"Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream","volume":"193","author":"Engilbertsson","year":"2014","journal-title":"J Urol"},{"key":"key2024091819533000_ref10-bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.eururo.2011.12.009","article-title":"Diagnostic efficacy of [11C]choline positron emission tomography\/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy","volume":"61","author":"Maurer","year":"2012","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref11-bib11","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.crad.2011.05.019","article-title":"Bladder cancer: evaluation of staging accuracy using dynamic MRI","volume":"66","author":"Rajesh","year":"2011","journal-title":"Clin Radiol"},{"key":"key2024091819533000_ref12-bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2009.05.014","article-title":"FDG-PET\/CT for the preoperative lymph node staging of invasive bladder cancer","volume":"57","author":"Swinnen","year":"2010","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref13-bib13","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1016\/j.ejrad.2012.06.010","article-title":"Prospective evaluation of MRI, (1)(1)C-acetate PET\/CT and contrast-enhanced CT for staging of bladder cancer","volume":"81","author":"Vargas","year":"2012","journal-title":"Eur J Radiol"},{"key":"key2024091819533000_ref14-bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euo.2019.09.008","article-title":"A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients","volume":"3","author":"Russell","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"key2024091819533000_ref15-bib15","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.eururo.2006.05.046","article-title":"Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature","volume":"50","author":"Fahmy","year":"2006","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref16-bib16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.juro.2009.06.041","article-title":"Longer wait times increase overall mortality in patients with bladder cancer","volume":"182","author":"Kulkarni","year":"2009","journal-title":"J Urol"},{"key":"key2024091819533000_ref17-bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0022-5347(05)00070-4","article-title":"Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study","volume":"175","author":"Mahmud","year":"2006","journal-title":"J Urol"},{"key":"key2024091819533000_ref18-bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14040","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer","volume":"14","author":"Mowatt","year":"2010","journal-title":"Health Technol Assess"},{"key":"key2024091819533000_ref19-bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bju.12468","article-title":"Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) Urological Tumour Registry","volume":"113","author":"Boustead","year":"2014","journal-title":"BJU Int"},{"key":"key2024091819533000_ref20-bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bju.12032","article-title":"A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years","volume":"112","author":"Bryan","year":"2013","journal-title":"BJU Int"},{"key":"key2024091819533000_ref21-bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ucl.2013.07.004","article-title":"Office-based management of nonmuscle invasive bladder cancer","volume":"40","author":"Meeks","year":"2013","journal-title":"Urol Clin North Am"},{"key":"key2024091819533000_ref22-bib22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref23-bib23","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00345-022-03969-6","article-title":"The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations","volume":"40","author":"Del Giudice","year":"2022","journal-title":"World J Urol"},{"key":"key2024091819533000_ref24-bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2019.09.029","article-title":"Prospective assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection","volume":"77","author":"Del Giudice","year":"2020","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref25-bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.semnuclmed.2021.12.004","article-title":"PET\/CT in bladder cancer: an update","volume":"52","author":"Bouchelouche","year":"2022","journal-title":"Semin Nucl Med"},{"key":"key2024091819533000_ref26-bib26","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.4172\/1948-5956.S14-001","article-title":"PET\/CT and MRI in bladder cancer","volume":"S14","author":"Bouchelouche","year":"2012","journal-title":"J Cancer Sci Ther"},{"key":"key2024091819533000_ref27-bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1148\/radiol.2511080873","article-title":"Urinary bladder cancer: diffusion-weighted MR imaging: accuracy for diagnosing T stage and estimating histologic grade","volume":"251","author":"Takeuchi","year":"2009","journal-title":"Radiology"},{"key":"key2024091819533000_ref28-bib28","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ejrad.2013.08.008","article-title":"Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect","volume":"82","author":"Donaldson","year":"2013","journal-title":"Eur J Radiol"},{"key":"key2024091819533000_ref29-bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/jmri.24227","article-title":"MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging","volume":"38","author":"Takeuchi","year":"2013","journal-title":"J Magnet Reson Imaging"},{"key":"key2024091819533000_ref30-bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"key2024091819533000_ref31-bib31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bju.14808","article-title":"Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification","volume":"124","author":"Ward","year":"2019","journal-title":"BJU Int"},{"key":"key2024091819533000_ref32-bib32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2009.01.002","article-title":"The updated EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"55","author":"Stenzl","year":"2009","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref33-bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2214\/AJR.12.10348","article-title":"Utility of quantitative MRI metrics for assessment of stage and grade of urothelial carcinoma of the bladder: preliminary results","volume":"201","author":"Rosenkrantz","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"key2024091819533000_ref34-bib34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1258\/ar.2012.120069","article-title":"Bladder cancer: utility of MRI in detection of occult muscle-invasive disease","volume":"53","author":"Rosenkrantz","year":"2012","journal-title":"Acta Radiol"},{"key":"key2024091819533000_ref35-bib35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1308\/003588410X12664192076935","article-title":"Mechanisms of recurrence of Ta\/T1 bladder cancer","volume":"92","author":"Bryan","year":"2010","journal-title":"Ann Royal Coll Surg Engl"},{"key":"key2024091819533000_ref36-bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00345-009-0398-9","article-title":"Bladder cancer: new TUR techniques","volume":"27","author":"Wilby","year":"2009","journal-title":"World J Urol"},{"key":"key2024091819533000_ref37-bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1464-410X.2004.04997.x","article-title":"Socio-economic deprivation and survival in bladder cancer","volume":"94","author":"Begum","year":"2004","journal-title":"BJU Int"},{"key":"key2024091819533000_ref38-bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2021.02.021","article-title":"Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study","volume":"80","author":"Bryan","year":"2021","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref39-bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1464-410X.1994.tb07482.x","article-title":"Rapid diagnostic service for patients with haematuria","volume":"73","author":"Lynch","year":"1994","journal-title":"Br J Urol"},{"key":"key2024091819533000_ref40-bib40","volume-title":"NHS Payment System","author":"NHSEngland","year":"2020"},{"key":"key2024091819533000_ref41-bib41","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic predictors of good outcome, recurrence or progression in High grade T1 non-muscle invasive bladder cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Res"},{"key":"key2024091819533000_ref42-bib42","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref43-bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40814-020-00713-y","article-title":"Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial","volume":"6","author":"Mintz","year":"2020","journal-title":"Pilot Feasibil Stud"},{"key":"key2024091819533000_ref44-bib44","doi-asserted-by":"crossref","first-page":"e000038","DOI":"10.1136\/bmjonc-2023-000038","article-title":"Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath","volume":"2","author":"Mintz","year":"2023","journal-title":"BMJ Oncol"},{"key":"key2024091819533000_ref45-bib45","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/cncr.32048","article-title":"Delays in radical cystectomy for muscle-invasive bladder cancer","volume":"125","author":"Chu","year":"2019","journal-title":"Cancer"},{"key":"key2024091819533000_ref46-bib46","volume-title":"Median Pathway Analysis by Patient Demographics, Stage at Diagnosis, Route to Diagnosis, and Geography","author":"Cancer Alliance Data Evidence and Analysis Service (CADEAS)","year":"2018"},{"key":"key2024091819533000_ref47-bib47","doi-asserted-by":"crossref","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"key2024091819533000_ref48-bib48","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1046\/j.1464-410X.2002.02776.x","article-title":"Delay and survival in bladder cancer","volume":"89","author":"Wallace","year":"2002","journal-title":"BJU Int"},{"key":"key2024091819533000_ref49-bib49","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cncr.24052","article-title":"Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-Medicare analysis","volume":"115","author":"Gore","year":"2009","journal-title":"Cancer"},{"key":"key2024091819533000_ref50-bib50","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0022-5347(05)00644-0","article-title":"Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival","volume":"175","author":"Lee","year":"2006","journal-title":"J Urol"},{"key":"key2024091819533000_ref51-bib51","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jama.1983.03340100058033","article-title":"Landmark article May 28, 1910: removal of neoplasms of the urinary bladder By Edwin Beer","volume":"250","author":"Beer","year":"1983","journal-title":"JAMA"},{"key":"key2024091819533000_ref52-bib52","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"key2024091819533000_ref53-bib53","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.urology.2014.06.032","article-title":"Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens","volume":"84","author":"Cai","year":"2014","journal-title":"Urology"},{"key":"key2024091819533000_ref54-bib54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euf.2021.04.005","article-title":"Accuracy of transurethral resection of the bladder in detecting variant histology of bladder cancer compared with radical cystectomy","volume":"8","author":"Lonati","year":"2022","journal-title":"Eur Urol Focus"},{"key":"key2024091819533000_ref55-bib55","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2024091819533000_ref56-bib56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref57-bib57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MOU.0000000000001022","article-title":"The past, present, and future of pT0 in bladder cancer clinical trials","volume":"32","author":"Schober","year":"2022","journal-title":"Curr Opin Urol"},{"key":"key2024091819533000_ref58-bib58","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"key2024091819533000_ref59-bib59","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djac162","article-title":"Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease","volume":"114","author":"Awasthi","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"key2024091819533000_ref60-bib60","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"key2024091819533000_ref61-bib61","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"key2024091819533000_ref62-bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1308\/rcsann.2016.0246","article-title":"Prediction of histological stage based on cytoscopic appearances of newly diagnosed bladder tumours","volume":"98","author":"During","year":"2016","journal-title":"Ann R Coll Surg Engl"},{"key":"key2024091819533000_ref63-bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer \u2013 2020 Update Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"key2024091819533000_ref64-bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bju.15899","article-title":"The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway","volume":"131","author":"Eldred-Evans","year":"2023","journal-title":"BJU Int"},{"key":"key2024091819533000_ref65-bib65","first-page":"138","article-title":"Histology at transurethral resection of bladder tumor and radical cystectomy for bladder cancer: insights from population-based data","volume":"15","author":"Dyer","year":"2021","journal-title":"Can Urol Assoc J"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2045876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/DEHT5407\/DEHT5407.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2045876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T14:30:29Z","timestamp":1726669829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/DEHT5407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":65,"alternative-id":["10.3310\/DEHT5407"],"URL":"https:\/\/doi.org\/10.3310\/deht5407","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2016","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"09-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}